Additive Assurance provides quality assurance solutions for metal additive manufacturing through process monitoring and data analytics. The company enhances the integrity and performance of 3D-printed metal components, minimizing defects and improving reliability in critical applications.

Gastric Alimetry develops a medical device that utilizes Body Surface Gastric Mapping to record and analyze gastric electrophysiology, aiding in the diagnosis of gastrointestinal disorders. This technology provides objective insights into gastric function and motility, enabling clinicians to identify the root causes of chronic gastric symptoms more effectively than traditional diagnostic methods.

The startup develops an autonomous two-seat aircraft that utilizes vertical takeoff and landing (VTOL) technology to enable air travel from locations equipped with landing pads. This aircraft provides a fast, safe, and environmentally friendly transportation option, effectively bypassing ground traffic congestion.

Azaneo provides an electric weed‑control system that uses a rapid electroporation pulse to instantly kill individual weeds without heat, chemicals, or residue. The technology delivers the lowest energy per weed globally, works in any weather, and protects surrounding crops, offering commercial farmers a sustainable, chemical‑free alternative for long‑lasting weed management.

CyAmast provides IoT network security and analytics solutions specifically designed for government entities to detect and protect against cyber threats. Their technology enhances network resilience by identifying vulnerabilities and monitoring real-time data traffic to prevent unauthorized access.

ElectraLith develops a direct lithium extraction and refining technology that produces battery-grade lithium hydroxide in a single, modular process without the use of water or chemicals. This method addresses the environmental impact of traditional lithium production by utilizing renewable energy, enhancing sustainability in lithium supply chains.

The startup develops RNA-targeted therapeutics designed to regulate gene expression for cancer treatment. By focusing on RNA biology, the company aims to provide precise interventions that can improve patient outcomes in oncology.

Hysata provides a cloud‑native data lake platform that combines high‑throughput object storage with a searchable metadata index and serverless transformation pipelines. The service offers a unified API for ingest, catalog, and query of petabyte‑scale unstructured datasets, along with native compute connectors and enterprise‑grade security controls, enabling AI and analytics teams to process data in place while minimizing storage costs.

Inosi Therapeutics develops small molecule inhibitors targeting the Insulin Regulated Aminopeptidase (IRAP) pathway to reverse fibrosis, a condition that leads to tissue scarring and organ dysfunction in chronic diseases. With no existing drugs capable of reversing fibrosis, Inosi's therapies aim to fill a significant gap in treatment options for the 10% of the population affected by fibrotic conditions.

Jetra Therapeutics is developing a therapeutic approach to treat obesity-related liver disease by targeting cellular stress mechanisms in hepatocytes. This treatment aims to improve liver function and reduce the risk of complications associated with fatty liver disease.

Kira Biotech develops novel immunomodulatory drugs targeting immune system disorders, utilizing advanced therapeutic antibody technologies to enhance treatment efficacy. The company focuses on addressing unmet medical needs in immunology, particularly for conditions such as rheumatoid arthritis and other immune-mediated diseases.

OptiGrid provides battery and renewable asset optimisation software for electricity markets using proprietary machine learning models. The platform enables intelligent energy trading, risk management, and asset health monitoring to maximise lifetime returns. Its core product, OptiBidder, offers advanced price forecasting and bidding models tailored for specific energy markets.

RAGE Biotech is developing splice-switching oligonucleotide (SSO) therapeutics that inhibit the Receptor for Advanced Glycation End-products (RAGE) to target chronic inflammatory diseases such as COPD and severe asthma. By utilizing RNA-targeting technologies, the company aims to provide effective treatments for patients suffering from difficult-to-treat inflammatory conditions.

Develops a therapeutic technology platform that improves immune system recognition and response to tissues, malignancies, and pathogens. This approach targets autoimmune diseases and cancer, aiming to enhance treatment efficacy and patient outcomes by enabling the immune system to better identify and combat these conditions.